{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:10:13Z","timestamp":1790007013918,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000098","name":"Clinical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["ZIA BC 011823"],"award-info":[{"award-number":["ZIA BC 011823"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jtct.2024.05.010","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T14:00:24Z","timestamp":1715868024000},"page":"776-787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies"],"prefix":"10.1016","volume":"30","author":[{"given":"Rebecca A.","family":"Gardner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdi","family":"Elsallab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Farnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Fraint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bambi","family":"Grilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Bateman-House","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan O.","family":"Oluwole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayne H.","family":"Rouce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Komanduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saar","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtct.2024.05.010_bib0001","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jtct.2024.05.010_bib0002","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jtct.2024.05.010_bib0003","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.jtct.2024.05.010_bib0004","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"10299","key":"10.1016\/j.jtct.2024.05.010_bib0005","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"10297","key":"10.1016\/j.jtct.2024.05.010_bib0006","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jtct.2024.05.010_bib0007","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.05.010_bib0008","unstructured":"Approved Cellular and Gene Therapy Products. FDA. 2024. Updated 02\/21\/2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products9."},{"issue":"23","key":"10.1016\/j.jtct.2024.05.010_bib0009","first-page":"e91","article-title":"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia. Reply","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jtct.2024.05.010_bib0010","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jtct.2024.05.010_bib0011","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jtct.2024.05.010_bib0012","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene Autotemcel Gene Therapy for Non-beta(0)\/beta(0) Genotype beta-Thalassemia","volume":"386","author":"Locatelli","year":"2022","journal-title":"N Engl J Med"},{"issue":"7197","key":"10.1016\/j.jtct.2024.05.010_bib0013","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/453840a","article-title":"Translational research: crossing the valley of death","volume":"453","author":"Butler","year":"2008","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.jtct.2024.05.010_bib0014","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.05.010_bib0015","unstructured":"ADA-SCID gene therapy trials to resume in 2023. 2022. https:\/\/primaryimmune.org\/resources\/news-articles\/ada-scid-gene-therapy-trials-resume-2023"},{"key":"10.1016\/j.jtct.2024.05.010_bib0016","unstructured":"Pagliarulo N. Bluebird to withdraw gene therapy from Germany after dispute over price. https:\/\/www.biopharmadive.com\/news\/bluebird-withdraw-zynteglo-germany-price\/598689\/17."},{"issue":"5","key":"10.1016\/j.jtct.2024.05.010_bib0017","first-page":"365","article-title":"The Cost of Biotech Innovation: Exploring Research and Development Costs of Cell and Gene Therapies","volume":"37","author":"Sabatini","year":"2023","journal-title":"Pharmaceut Med"},{"issue":"7","key":"10.1016\/j.jtct.2024.05.010_bib0018","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jcyt.2022.03.007","article-title":"Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products","volume":"24","author":"Cuende","year":"2022","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/j.jtct.2024.05.010_bib0019","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ajh.26519","article-title":"Results of ARI-0001 CART19 cell therapy in patients with relapsed\/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease","volume":"97","author":"Ortiz-Maldonado","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2024.05.010_bib0020","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","article-title":"CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19(+) Relapsed\/Refractory Malignancies","volume":"29","author":"Ortiz-Maldonado","year":"2021","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.jtct.2024.05.010_bib0021","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41409-021-01463-y","article-title":"The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001","volume":"57","author":"Trias","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"19-20","key":"10.1016\/j.jtct.2024.05.010_bib0022","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1089\/hum.2021.168","article-title":"Is Hospital Exemption an Alternative or a Bridge to European Medicines Agency for Developing Academic Chimeric Antigen Receptor T-Cell in Europe? Our Experience with ARI-0001","volume":"32","author":"Juan","year":"2021","journal-title":"Hum Gene Ther"},{"issue":"17","key":"10.1016\/j.jtct.2024.05.010_bib0023","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.05.010_bib0024","unstructured":"Charging for Investigational Drugs Under an IND. 2024. Questions and Answers Guidance for Industry. https:\/\/www.fda.gov\/media\/176308\/download25."},{"issue":"1","key":"10.1016\/j.jtct.2024.05.010_bib0025","first-page":"26","article-title":"Paying for Unapproved Products","volume":"11","author":"Folkers","year":"2020","journal-title":"Wake Forest Journal of Health Law and Policy"},{"key":"10.1016\/j.jtct.2024.05.010_bib0026","unstructured":"Marsden GT, Adrian; Pearson, SD; Dreitlein, Bill; Henshall, Chris. Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for the Value. https:\/\/icer.org\/wp-content\/uploads\/2020\/11\/ICER-Gene-Therapy-White-Paper-030317.pdf27."},{"key":"10.1016\/j.jtct.2024.05.010_bib0027","unstructured":"Categorization of Inestigational Device Exemption (IDE) Devices to Assist the Centers for Medicare and Medicaid Servies (CMS) with Coverage Decisions. 2017. Guidance for Sponsors, Clinical investigators, Industry, institutional Review Boards, and Food and Drug Administration Staff. https:\/\/www.fda.gov\/media\/98578\/download28."},{"key":"10.1016\/j.jtct.2024.05.010_bib0028","unstructured":"Europe-wide group launched to boost access to life-saving gene therapies. 2022. https:\/\/www.gosh.nhs.uk\/news\/euro-group-to-boost-access-to-life-saving-gene-therapies\/29."},{"key":"10.1016\/j.jtct.2024.05.010_bib0029","unstructured":"Making Genetic Therpies Affordable And Accessible [White Paper]. 2023. https:\/\/innovativegenomics.org\/atf-report\/30."},{"key":"10.1016\/j.jtct.2024.05.010_bib0030","unstructured":"EMA pilot offers enhanced support to academic and non-profit devleopers of advanced therapy medicinal products. 2022. https:\/\/www.ema.europa.eu\/en\/news\/ema-pilot-offers-enhanced-support-academic-and-non-profit-developers-advanced-therapy-medicinal-products"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672400407X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672400407X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T02:16:18Z","timestamp":1754014578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672400407X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S266663672400407X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.05.010","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}